



Press Release

STADA plans to hand German logistics business over to a globally active and well-known logistics company

Bad Vilbel, October 10, 2014 – STADA Arzneimittel AG plans to hand its German logistics activities over to a globally active and well-known logistics company. It is planned for all STADA logistics activities at the Florstadt and Bad Vilbel locations to be transferred to a service provider in the first quarter of 2015. It does not include the sale of infrastructure. In the context of the planned operational transfer, all affected STADA employees shall be transferred to the new employer.

Outsourcing STADA's logistics would allow for the avoidance of substantial future investments. Back in August, STADA decided that only one subsidiary, ALIUD PHARMA, would participate in tender business. "Against the backdrop of increasing cost pressure in Germany and STADApHarm's corresponding withdrawal from tender business, our need for logistics services has changed to the point where it is no longer attractive for us to carry out our own logistics activities in Germany. As opposed to us, a logistics company can compensate for fluctuation with third-party business", says Dr. Matthias Wiedenfels, STADA's Executive Board member responsible for business development and central services.

Approximately 160 employees currently work at STADA's two distribution and service centers in Florstadt and Bad Vilbel. With the new employer, it would be possible to keep the Florstadt location over the long term and even expand it.

Executive Board: Hartmut Retzlaff (Chairman) / Helmut Kraft / Dr. Matthias Wiedenfels
Chairman of the Supervisory Board: Dr. Martin Abend



About STADA Arzneimittel AG:

STADA Arzneimittel AG is a publicly-listed company with headquarters in Bad Vilbel, Germany. STADA consistently focuses on a multi-pillar strategy of generics and branded products (OTC) with an increasingly international market orientation. The Group is the only independent generics producer in Germany. Worldwide, STADA is represented in 29 countries with 47 subsidiaries. Branded products such as Grippostad, Ladival and Mobilat are among the highest selling in their product category in Germany. In financial year 2013, STADA achieved Group sales of Euro 2,014.4 million, adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of Euro 415.2 million and adjusted net income of Euro 160.6 million. As of December 31, 2013, STADA employed 9,825 people worldwide.

For more information, please contact:

STADA Arzneimittel AG
Media Relations
Stadastraße 2-18
61118 Bad Vilbel – Germany
Tel.: +49(0) 6101 603-165
Fax: +49(0) 6101 603-506
E-mail: press@stada.de
Web: www.stada.de

Executive Board: Hartmut Retzlaff (Chairman) / Helmut Kraft / Dr. Matthias Wiedenfels
Chairman of the Supervisory Board: Dr. Martin Abend